Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A randomized, partially double-blind placebo- and active-controlled, single dose, four period, crossover QT/QTc study to assess the effect of CIN-102 on cardiac repolarization in healthy individuals

Trial Profile

A randomized, partially double-blind placebo- and active-controlled, single dose, four period, crossover QT/QTc study to assess the effect of CIN-102 on cardiac repolarization in healthy individuals

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 12 May 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Deudomperidone (Primary)
  • Indications Gastroparesis
  • Focus Adverse reactions; Registrational

Most Recent Events

  • 08 May 2023 Results published in the CinRx Pharma Media Release
  • 07 May 2023 According to CinRx Pharma Media Release, data from this study presented at 2023 Digestive Disease Week Conference
  • 02 May 2023 According to a CinDome Pharma media release, data from this study will be presented at the at 2023 Digestive Disease Week Conference.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top